Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + cisplatin + gemcitabine + toripalimab
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination regimen is a chemo-immunotherapy protocol consisting of the multi-target tyrosine kinase inhibitor anlotinib, the PD-1 checkpoint inhibitor toripalimab, and the standard-of-care chemotherapy doublet gemcitabine and cisplatin (GP). It is primarily being investigated as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). The rationale behind this four-drug combination is to leverage the anti-angiogenic properties of anlotinib, which targets VEGFR, FGFR, and PDGFR, alongside the immune-potentiating effects of toripalimab to overcome the immunosuppressive tumor microenvironment. These targeted agents are combined with the cytotoxic effects of gemcitabine and cisplatin to maximize tumor cell death and improve clinical outcomes in advanced nasopharyngeal malignancies.
- Brand names
- FukanghuaTuoyi
- Other names
- GP chemotherapy + anlotinib + toripalimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on anlotinib + cisplatin + gemcitabine + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + cisplatin + gemcitabine + toripalimab.